Article Text

Download PDFPDF
SGLT2 inhibitors and cardiovascular outcomes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A large observational study has investigated the cardiovascular effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors in new users compared with new users of other glucose-lowering drugs.1 Previously published studies in patients with type 2 diabetes and a high cardiovascular risk profile have reported reductions in cardiovascular outcomes with the SGLT2 inhibitors inhibitors ▼ empagliflozin and ▼ canagliflozin.2,3

This observational study compared cardiovascular mortality and morbidity in people with type 2 diabetes (mean age 61 years), of whom 25% had cardiovascular disease.1 The …

View Full Text